Shoosmiths has advised new company Haversham Holdings on their decision to float on the Alternative Investment Market (AIM).

Haversham Holdings is a new Group formed by Avril Palmer-Baunack former executive chairman of Stobart group and former chief executive of Autologic, along with the support of Marwyn, the specialist investment management company. Avril will drive the business alongside fellow executive directors James Corsellis and Mark Brangstrup Watts.

Christian Berner Tech Trade AB’s new share issue was fully subscribed and the shares are listed on First North. The first day of trading was 20 October 2014.

Vinge acted as the company’s legal adviser. Vinge’s team consisted of responsible partner Olof Gisland, partner Anders Strid and associates Anna Hofling Johansson, Emma Kero Ljungberg and Daniel Lennartsson.

Slaughter and May is advising SVG Capital plc (SVG Capital) in relation to a return of up to £50 million to shareholders by way of a tender offer for ordinary shares and a subsequent repurchase by SVG Capital. The tender offer is being carried out pursuant to the authority granted by shareholders at SVG Capital’s annual general meeting on 28 March 2014 authorising tender offers of up to £150 million. The tender offer is the second in the series.

CONTACTS

Herbert Smith Freehills is advising UBS AG, Australia Branch and CIMB Capital Markets (Australia) Ltd in relation to their role as bookrunners and joint lead managers of Centuria Property Funds Limited’s (as Responsible Entity of Centuria Metropolitan REIT No.1 and Centuria Metropolitan REIT No.2 (together, the Stapled Funds)) initial public offering of stapled securities in the Stapled Funds (IPO) and listing on the Australian Securities Exchange (ASX).

Kungsleden AB (publ) has implemented a rights issue of SEK 1.6 billion with pre-emptive rights for the shareholders.

Kungsleden is a Swedish real property company, listed on NASDAQ Stockholm since 1999, with a real property portfolio consisting of commercial properties and modular buildings.

Kungsleden has been advised by Mannheimer Swartling on the rights issue. The firm’s team primarily included Eva Hägg, Nils Nostell, Mirka Ylinen Gorne and Louise Sannebrink.

Linklaters advised consortium banks, led by JP Morgan as Global Coordinator, in the successful IPO of Swiss biotechnology company Molecular Partners. The proposition also included an offer to institutional investors in the United States.

The offer price for the shares was 22.40 Swiss francs per share, representing a market capitalization of around 485 million Swiss francs. Listing of the shares of Molecular Partners and the first day of trading on the SIX Swiss Exchange took place on November 5, 2014.

The Charles Russell Speechlys Corporate team has recently advised Arden Partners plc in its role as financial adviser, sponsor and broker to Macfarlane Group plc in connection with a £3m placing of new shares on the Main Market of the London Stock Exchange.

Macfarlane Group plc is a leading specialist UK distributor of protective packaging materials.

The proceeds of the placing were used to partly fund a simultaneous acquisition of the entire issued share capital of Network Packaging Ltd (a packaging materials distributor).

Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company, based in Schlieren-Zurich, Switzerland, that develops a new class of therapies known as DARPins, closed its initial public offering and listing on the SIX Swiss Exchange AG. 4,400,000 shares of Molecular Partners AG were placed at CHF 22.40 per share, leading to a market capitalization of Molecular Partners AG of approximately CHF 485 million on a fully-diluted basis (prior to exercise of the over-allotment option granted to the underwriting banks).

HWL Ebsworth Lawyers has advised Simonds Group on its Initial Public Offering (IPO) on the Australian Securities Exchange (ASX) of 90.4 million shares, valued at $1.78, raising a total of $161 million. Shares in Simonds Group are scheduled to begin trading on 17 November 2014 under the ASX code SIO. The market capitalisation at the offer price values the company at $269.5 million.

Molecular Partners AG, a Swiss biopharmaceutical company, closed its Initial Public Offering (IPO) on 7 November 2014. The shares were first listed and traded on SIX Swiss Exchange on 5 November 2014. It was the first IPO in this industry at the SIX Swiss Exchange in five years.

J.P. Morgan Securities plc acted as Global Coordinator and together with UBS AG as Joint Bookrunner. Cowen and Company and Bank am Bellevue AG acted as Co-Managers.